BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 14 2025
0mins
Should l Buy ?
Source: PRnewswire
Corporate Update: BrainStorm Cell Therapeutics announced the initiation of a Phase 3b clinical trial for its ALS therapy, NurOwn®, following FDA clearance, and highlighted encouraging survival data from its Expanded Access Program.
Financial Overview: The company reported a net loss of approximately $2.9 million for Q2 2025, with cash reserves of about $1.03 million, while also noting a decrease in general administrative expenses compared to the previous year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
